Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 6/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | DHODH | Q02127 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.36 |
| ▸ | KDM1A | O60341 | 2/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
| ▸ | PTGES | O14684 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5502067 | 0.82 | MAOB (0.52) | MAOBNPSR1PDE4BMEN1HTT | |
| SCHEMBL9057024 | 0.82 | ALPL (0.43) | MAOBPDE4BMEN1HTTKMT2A | |
| SCHEMBL10973026 | 0.81 | MAOB (0.51) | MAOBNPSR1PDE4BMEN1HTT | |
| SCHEMBL11623295 | 0.79 | MAOB (0.52) | MAOBNPSR1PDE4BMEN1HTT | |
| SCHEMBL4023321 | 0.74 | MEN1 (0.49) | MEN1HTTKMT2ALMNAALDH1A1 | |
| SCHEMBL15594553 | 0.73 | MET (0.42) | NPSR1MEN1KMT2AALDH1A1 | |
| SCHEMBL9326495 | 0.73 | HDAC6 (0.56) | DHODHHDAC1KDM1AHDAC2HDAC11 | |
| SCHEMBL2615352 | 0.72 | KMO (0.43) | KMT2AGRM2 | |
| SCHEMBL13520606 | 0.72 | GRM2 (0.44) | MAOBMEN1KMT2AALDH1A1GRM2 | |
| SCHEMBL15594548 | 0.70 | MET (0.44) | NPSR1MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190083474-A1 | AZA-BICYCLOALKYL ETHERS AND THEIR USE AS ALPHA7-NACHR AGONISTS | NOVARTIS AG (CH) | 2019-03-21 | — | — | US | disclosed |
| US-20180078536-A1 | AZA-BICYCLOALKYL ETHERS AND THEIR USE AS ALPHA7-NACHR AGONISTS | NOVARTIS AG (CH) | 2018-03-22 | — | — | US | disclosed |
| US-9849117-B2 | Aza-bicycloalkyl ethers and their use as alpha7-nachr agonists | NOVARTIS AG (CH) | 2017-12-26 | — | — | US | disclosed |
| US-9657010-B2 | Substituted quinuclidines as alpha 7-nicotinic acetylcholine receptor activity modulators | NOVARTIS AG (CH) | 2017-05-23 | — | — | US | disclosed |
| US-20170112814-A1 | AZA-BICYCLOALKYL ETHERS AND THEIR USE AS ALPHA7-NACHR AGONISTS | NOVARTIS AG (CH) | 2017-04-27 | — | — | US | disclosed |
| US-9567343-B2 | Aza-bicyloalkyl ethers and their use as alpha7-nachr agonists | NOVARTIS AG (CH) | 2017-02-14 | — | — | US | disclosed |
| US-9475811-B2 | 1-aza-bicyclo[3.3.1]nonanes | NOVARTIS AG (CH) | 2016-10-25 | — | — | US | disclosed |
| US-20150183794-A1 | AZA-BICYLOALKYL ETHERS AND THEIR USE AS ALPHA7-NACHR AGONISTS | NOVARTIS AG (CH) | 2015-07-02 | — | — | US | disclosed |
| US-9012451-B2 | Aza-bicycloalkyl ethers and their use as ALPHA7-nachr agonists | NOVARTIS AG (CH) | 2015-04-21 | — | — | US | disclosed |
| US-20150087650-A1 | 1-AZA-BICYCLO[3.3.1]NONANES | NOVARTIS AG (CH) | 2015-03-26 | — | — | US | disclosed |
| CN-1325493-C | Aza-bicycloalkyl ethers and their use as alpha7-nachr agonist | NOVARTIS AG (CH) | 2007-07-11 | — | — | CN | disclosed |
| CN-1964968-A | 1-aza-bicyclo[3.3.1]nonanes | NOVARTIS AG (CH) | 2007-05-16 | — | — | CN | disclosed |
| EP-1776360-A1 | 3-(HETEROARYL-OXY)-2-ALKYL-1-AZA-BICYCLOALKYL DERIVATIVES AS ALPHA.7-NACHR LIGANDS FOR THE TREATMENT OF CNS DISEASES. | Novartis AG (CH) | 2007-04-25 | — | — | EP | disclosed |
| EP-1761533-A1 | 1-AZA-BICYCLO[3.3.1]NONANES | Novartis AG (CH) | 2007-03-14 | — | — | EP | disclosed |
| US-20060167002-A1 | Aza-bicycloalkyl ethers and their use as alpha7-nachr agonists | FEUERBACH DOMINIK | 2006-07-27 | — | — | US | disclosed |
| WO-2006005608-A1 | 3-(HETEROARYL-OXY)-2-ALKYL-1-AZA-BICYCLOALKYL DERIVATIVES AS ALPHA.7-NACHR LIGANDS FOR THE TREATMENT OF CNS DISEASES | NOVARTIS AG (CH) | 2006-01-19 | — | — | WO | disclosed |
| WO-2005123732-A1 | 1-AZA-BICYCLO[3.3.1]NONANES | NOVARTIS AG (CH) | 2005-12-29 | — | — | WO | disclosed |
| CN-1678611-A | Aza-bicycloalkyl ethers and their use as alpha7-nachr agonist | NOVARTIS AG (CH) | 2005-10-05 | — | — | CN | disclosed |
| EP-1537104-A1 | AZA-BICYCLOALKYL ETHERS AND THEIR USE AS ALPHA7-NACHR AGONIST | Novartis AG (CH) | 2005-06-08 | — | — | EP | disclosed |
| WO-2004022556-A1 | AZA-BICYCLOALKYL ETHERS AND THEIR USE AS ALPHA7-NACHR AGONIST | NOVARTIS AG (CH) | 2004-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150183794-A1 | AZA-BICYLOALKYL ETHERS AND THEIR USE AS ALPHA7-NACHR AGONISTS | CHRNA7, CHRNA1, CHRNE | MAOB 513/4885NPSR1 373/4885PDE4B 384/4885 |
| US-20170112814-A1 | AZA-BICYCLOALKYL ETHERS AND THEIR USE AS ALPHA7-NACHR AGONISTS | CHRNA7, CHRNA1, CHRNE | MAOB 426/4885NPSR1 435/4885PDE4B 302/4885 |
| US-20180078536-A1 | AZA-BICYCLOALKYL ETHERS AND THEIR USE AS ALPHA7-NACHR AGONISTS | CHRNA7, CHRNA1, CHRNE | MAOB 426/4885NPSR1 435/4885PDE4B 302/4885 |
| US-20060167002-A1 | Aza-bicycloalkyl ethers and their use as alpha7-nachr agonists | CHRNA7, CHRNA1, CHRNE | MAOB 406/4885NPSR1 536/4885PDE4B 173/4885 |
| US-20150087650-A1 | 1-AZA-BICYCLO[3.3.1]NONANES | CBR3, CBR1, ADCY3 | MAOB 1023/4885NPSR1 387/4885PDE4B 680/4885 |
| US-20190083474-A1 | AZA-BICYCLOALKYL ETHERS AND THEIR USE AS ALPHA7-NACHR AGONISTS | CHRNA7, CHRNA1, CHRNE | MAOB 426/4885NPSR1 435/4885PDE4B 302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.